Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Brest – page 23

584 clinical trials in Brest, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Brest at a glance
584
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

584 trials in Brest

Open in trial search

Rheumatoid arthritis

Recruiting

Study Comparing Methotrexate or Leflunomide with Targeted Therapy vs. Methotrexate or Leflunomide with Drug Combination for Rheumatoid Arthritis Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

HER2 positive breast cancer

Recruiting

Study on Reducing Treatment for Patients with HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination After 2 Years of Controlled Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Unicancer

Cutibacterium acnes infection

Recruiting

Study on Reducing Cutibacterium acnes in Shoulder Surgery for Men Using Benzoyl Peroxide and Ethanol-Povidone Iodine Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Povidone, Iodinated
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Bronchopulmonary aspergillosis

Recruiting

Study Comparing Itraconazole and Nebulised Amphotericin B with Itraconazole Alone for Patients with Chronic Pulmonary Aspergillosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Itraconazole
  • Sponsor:Centre Hospitalier Universitaire De Poitiers

Septic shock

Recruiting

Study on Landiolol Hydrochloride and Sodium Chloride for Reducing Mortality in Patients with Septic Shock and High Heart Rate

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Myelin oligodendrocyte glycoprotein antibody-associated disease

Recruiting

Study of Early versus Delayed Treatment with Azathioprine or Rituximab in Children with Anti-MOG Antibody Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

Cerebral haemorrhage

Recruiting

Study on Avoiding Anticoagulation with Apixaban for Patients with Intracerebral Hemorrhage

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Centre Hospitalier Universitaire De Lille

Acute lymphocytic leukaemia+1

Recruiting

Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Assistance Publique Hopitaux De Paris

Pancreatic carcinoma metastatic

Not yet recruiting

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel

Hidradenitis

Not yet recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Embolism

Not yet recruiting

A study to evaluate the effectiveness of REGN7508 for preventing blood clots in adults with solid tumors undergoing cancer treatment.

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Regn7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Sjogren's syndrome

Not yet recruiting

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Brest

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on head and neck squamous cell carcinoma, exploring innovative treatments combining radiotherapy with targeted therapies. Studies also examine new approaches for esophageal cancer and pancreatic adenocarcinoma.

  • Advanced Cancer Therapies
  • Combination Treatments
  • Targeted Therapeutics

Multiple trials are investigating novel drug combinations and immunotherapy approaches for various cancer types.

02 Autoimmune Conditions

Comprehensive research into Sjögren's syndrome treatment options, including innovative biological therapies and histopathological studies. Additional focus on rheumatoid arthritis and novel therapeutic approaches.

  • Biological Treatments
  • Disease Mechanisms
  • Treatment Response

Studies aim to understand disease mechanisms and evaluate new therapeutic options for autoimmune disorders.

03 Cardiovascular and Respiratory Studies

Investigation of treatments for pulmonary arterial hypertension and heart failure prevention. Research includes innovative drug combinations and preventive approaches for cardiovascular conditions.

  • Heart Failure Prevention
  • Hypertension Management
  • Asthma Control

Focus on developing effective treatments for chronic cardiovascular and respiratory conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.